Oral ondansetron in the prevention of chemotherapy-induced emesis in breast cancer patients

This publication has 11 references indexed in Scilit:

• Efficacy of Oral Ondansetron in the Prevention of Emesis in Outpatients Receiving Cyclophosphamide-based Chemotherapy
  Annals of Internal Medicine, 1993
• Efficacy of twice daily versus three times daily oral ondansetron in the prevention of chemotherapy induced emesis: A randomized, single-blind, multicentre study
  Clinical Oncology, 1992
• Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast Cancer
  Oncology, 1992
• Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
  European Journal of Cancer and Clinical Oncology, 1991
• Comparison of ondansetron with a combined regimen of alizapride and methylprednisolone in the prophylaxis of cisplatin-induced emesis in patients with lung cancer
  Published by Springer Nature ,1991
• Comparison of the 5-Hydroxytryptamine₃(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced Emesis
  New England Journal of Medicine, 1990
• GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting
  Cancer Chemotherapy and Pharmacology, 1989
• A prospective randomized phase III trial comparing combination chemotherapy with cyclophosphamide, fluorouracil, and either doxorubicin or epirubicin. French Epirubicin Study Group.
  Journal of Clinical Oncology, 1988
• Inhibition of cisplatin‐induced vomiting by selective 5‐hydroxytryptamine M‐receptor antagonism
  British Journal of Pharmacology, 1986
• Measuring the quality of life of cancer patients: the Functional Living Index-Cancer: development and validation.
  Journal of Clinical Oncology, 1984